Federal judges ban Allergan’s sovereign immunity scheme in a slapdown that will bolster inter partes review for years to come

Federal judges ban Allergan’s sovereign immunity scheme in a slapdown that will bolster inter partes review for years to come

Source: 
Endpoints
snippet: 

Allergan execs had thought they had found a clever way to dodge the threat of inter partes review of the patents for their big blockbuster Restasis. In the end, they $AGN paid a pretty price to bolster IPR, shutting and locking the door to the path they took — all while stewing in some intense public indignation over the effort.